CTLA4 and cancer: We recently assessed the impact of combination immune checkpoint blockade on the HIV reservoir in the AMC‐095 study, in which 40 PWH with cancer received nivolumab (anti‐PD‐1) alone (n = 33) or nivolumab and ipilimumab (anti‐CTLA‐4; n = 7).